<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Autism</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Autism</journal-id>
<journal-title-group>
<journal-title>Molecular Autism</journal-title>
</journal-title-group>
<issn pub-type="epub">2040-2392</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31893021</article-id>
<article-id pub-id-type="pmc">6937972</article-id>
<article-id pub-id-type="publisher-id">303</article-id>
<article-id pub-id-type="doi">10.1186/s13229-019-0303-3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Increased Ca<sup>2+</sup> signaling in <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons derived from ASD induced pluripotent stem cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Avazzadeh</surname>
<given-names>Sahar</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McDonagh</surname>
<given-names>Katya</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reilly</surname>
<given-names>Jamie</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yanqin</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boomkamp</surname>
<given-names>Stephanie D.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McInerney</surname>
<given-names>Veronica</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krawczyk</surname>
<given-names>Janusz</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fitzgerald</surname>
<given-names>Jacqueline</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feerick</surname>
<given-names>Niamh</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Sullivan</surname>
<given-names>Matthew</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jalali</surname>
<given-names>Amirhossein</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Forman</surname>
<given-names>Eva B.</given-names>
</name>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lynch</surname>
<given-names>Sally A.</given-names>
</name>
<xref ref-type="aff" rid="Aff8">8</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ennis</surname>
<given-names>Sean</given-names>
</name>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cosemans</surname>
<given-names>Nele</given-names>
</name>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peeters</surname>
<given-names>Hilde</given-names>
</name>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dockery</surname>
<given-names>Peter</given-names>
</name>
<xref ref-type="aff" rid="Aff13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Brien</surname>
<given-names>Timothy</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quinlan</surname>
<given-names>Leo R.</given-names>
</name>
<xref ref-type="aff" rid="Aff14">14</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gallagher</surname>
<given-names>Louise</given-names>
</name>
<address>
<email>LGALLAGH@tcd.ie</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8217-9811</contrib-id>
<name>
<surname>Shen</surname>
<given-names>Sanbing</given-names>
</name>
<address>
<email>sanbing.shen@nuigalway.ie</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0488 0789</institution-id><institution-id institution-id-type="GRID">grid.6142.1</institution-id><institution>Regenerative Medicine Institute, School of Medicine, Biomedical Science Building BMS-1021, </institution><institution>National University of Ireland Galway, </institution></institution-wrap>Dangan, Upper Newcastle, Galway, Ireland </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0605 1239</institution-id><institution-id institution-id-type="GRID">grid.256884.5</institution-id><institution>Department of Physiology, College of Life Science, </institution><institution>Hebei Normal University, </institution></institution-wrap>Shijiazhuang, China </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0488 0789</institution-id><institution-id institution-id-type="GRID">grid.6142.1</institution-id><institution>HRB Clinical Research Facility, </institution><institution>National University of Ireland (NUI), </institution></institution-wrap>Galway, Ireland </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0617 9371</institution-id><institution-id institution-id-type="GRID">grid.412440.7</institution-id><institution>Department of Haematology, </institution><institution>Galway University Hospital, </institution></institution-wrap>Galway, Ireland </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9705</institution-id><institution-id institution-id-type="GRID">grid.8217.c</institution-id><institution>School of Medicine, </institution><institution>Trinity College Dublin, </institution></institution-wrap>Dublin, Ireland </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0768 2743</institution-id><institution-id institution-id-type="GRID">grid.7886.1</institution-id><institution>School of Medicine, Conway Institute, </institution><institution>University College Dublin, </institution></institution-wrap>Belfield, Dublin 4, Ireland </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0514 6607</institution-id><institution-id institution-id-type="GRID">grid.412459.f</institution-id><institution>Children’s University Hospital, </institution></institution-wrap>Temple Street, Dublin, Ireland </aff>
<aff id="Aff8"><label>8</label>Department of Clinical Genetics, OLCHC, Dublin 12, Ireland </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0514 6607</institution-id><institution-id institution-id-type="GRID">grid.412459.f</institution-id><institution>Children’s University Hospital, </institution></institution-wrap>Temple St, Dublin, Ireland </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0768 2743</institution-id><institution-id institution-id-type="GRID">grid.7886.1</institution-id><institution>Academic Center on Rare Diseases, School of Medicine and Medical Science, </institution><institution>University College Dublin, </institution></institution-wrap>Dublin, Ireland </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0768 2743</institution-id><institution-id institution-id-type="GRID">grid.7886.1</institution-id><institution>UCD Academic Centre on Rare Diseases, School of Medicine and Medical Science, </institution><institution>University College Dublin, </institution></institution-wrap>Dublin, Ireland </aff>
<aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3338</institution-id><institution-id institution-id-type="GRID">grid.410569.f</institution-id><institution>Centre for Human Genetics, </institution><institution>University Hospital Leuven, </institution></institution-wrap>KU Leuven, 3000 Leuven, Belgium </aff>
<aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0488 0789</institution-id><institution-id institution-id-type="GRID">grid.6142.1</institution-id><institution>Centre for Microscopy and Imaging, Anatomy, School of Medicine, </institution><institution>National University of Ireland (NUI), </institution></institution-wrap>Galway, Ireland </aff>
<aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0488 0789</institution-id><institution-id institution-id-type="GRID">grid.6142.1</institution-id><institution>Physiology and Human Movement Laboratory, CÚRAM SFI Centre for Research in Medical Devices, School of Medicine, </institution><institution>National University of Ireland (NUI), </institution></institution-wrap>Galway, Ireland </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>52</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>12</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a high co-morbidity of epilepsy and associated with hundreds of rare risk factors. <italic>NRXN1</italic> deletion is among the commonest rare genetic factors shared by ASD, schizophrenia, intellectual disability, epilepsy, and developmental delay. However, how <italic>NRXN1</italic> deletions lead to different clinical symptoms is unknown. Patient-derived cells are essential to investigate the functional consequences of <italic>NRXN1</italic> lesions to human neurons in different diseases.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">Skin biopsies were donated by five healthy donors and three ASD patients carrying <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> deletions. Seven control and six <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> iPSC lines were derived and differentiated into day 100 cortical excitatory neurons using dual SMAD inhibition. Calcium (Ca<sup>2+</sup>) imaging was performed using Fluo4-AM, and the properties of Ca<sup>2+</sup> transients were compared between two groups of neurons. Transcriptome analysis was carried out to undercover molecular pathways associated with <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3"><italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons were found to display altered calcium dynamics, with significantly increased frequency, duration, and amplitude of Ca<sup>2+</sup> transients. Whole genome RNA sequencing also revealed altered ion transport and transporter activity, with upregulated voltage-gated calcium channels as one of the most significant pathways in <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons identified by STRING and GSEA analyses.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">This is the first report to show that human <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons derived from ASD patients’ iPSCs present novel phenotypes of upregulated VGCCs and increased Ca<sup>2+</sup> transients, which may facilitate the development of drug screening assays for the treatment of ASD.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Autism</kwd>
<kwd>Calcium signaling</kwd>
<kwd>Induced pluripotent stem cells</kwd>
<kwd>Neurons</kwd>
<kwd>
<italic>NRXN1α</italic>
</kwd>
<kwd>Transcriptome</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>Science Foundation Ireland</institution>
</funding-source>
<award-id>13/IA/1787</award-id>
<principal-award-recipient>
<name>
<surname>Shen</surname>
<given-names>Sanbing</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par10">Autism spectrum disorder (ASD) is a chronic neurodevelopmental disorder characterized by repetitive behavior and deficits in social interaction and communication skills. Epilepsy, intellectual disabilities, language delay, anxiety, and hyperactivity are highly comorbid with ASD [<xref ref-type="bibr" rid="CR1">1</xref>]. An increased ratio of synaptic excitation/inhibition (E/I) affecting neuroplasticity has been proposed as a common pathway for ASD [<xref ref-type="bibr" rid="CR2">2</xref>]. This has been linked to altered functional and structural connectivity. Additional evidence from post-mortem neuropathology also showed reduced parvalbumin and altered density/abundance of glutamatergic receptors including <italic>GRM5</italic> and <italic>GRIA1</italic> in ASD [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. On the other hand, overproduction of GABAergic neurons with <italic>FOXG1</italic> overexpression and accelerated cell cycle were also reported in induced pluripotent stem cells (iPSCs) of sporadic ASD with macrocephaly [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
<p id="Par11">For synaptic excitation, rare mutations in <italic>NRXN</italic>, <italic>NLGN</italic>, and <italic>SHANK</italic> are reported in individuals with ASD and intellectual disability, further supporting the E/I imbalance hypothesis [<xref ref-type="bibr" rid="CR7">7</xref>]. <italic>NRXN1</italic> and <italic>SHANK2</italic> are in fact the commonest rare genetic factors identified by a meta-analysis of multiple genetic studies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Notably, <italic>NRXN1</italic> deletions are shared by ASD [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR15">15</xref>], schizophrenia [<xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR20">20</xref>], intellectual disability [<xref ref-type="bibr" rid="CR21">21</xref>], ADHD [<xref ref-type="bibr" rid="CR22">22</xref>], and epilepsy [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR26">26</xref>]. Whereas most human deletions involve in 5′ of <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> with diverse clinical phenotypes, mouse <italic>Nrxn1α</italic><sup><italic>−/−</italic></sup> mutants display only mild behavioral deficit in nest building but are otherwise viable, fertile, and indistinguishable from wild-type littermates [<xref ref-type="bibr" rid="CR27">27</xref>]. This suggests that mouse and human may have different sensitivity to <italic>NRXN1α</italic> gene lesions.</p>
<p id="Par12">Three <italic>NRXN1</italic> family members (<italic>NRXN1-3</italic>) exist in the genome, and <italic>Nrxn1α</italic><sup><italic>−/−</italic></sup><italic>/Nrxn2α</italic><sup><italic>−/−</italic></sup><italic>/Nrxn3α</italic><sup><italic>−/−</italic></sup> triple knockout mice are impaired in Ca<sup>2+</sup>-triggered neurotransmitter release with altered expression of synaptic Ca<sup>2+</sup> channels and die of lung dysfunction [<xref ref-type="bibr" rid="CR28">28</xref>]. Ca<sup>2+</sup> concentration in neurons is tightly controlled by distinct influx/efflux mechanisms. Ca<sup>2+</sup> influx occurs commonly through voltage-gated calcium channels (VGCCs) on membrane [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], which facilitate a Ca<sup>2+</sup> rise during neuronal firing. The influx of Ca<sup>2+</sup> triggers vesicle exocytosis and neurotransmitter release. The long form of Nrnx1α has been shown to couple release-ready vesicles with metabotropic receptors, facilitating Ca<sup>2+</sup>-triggered exocytosis of neurons [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
<p id="Par13">In addition to the long NRXN1α isoforms, which interact with post-synaptic Neuroligins and influence both excitation and inhibition through coupling to GABAergic or NMDA/AMPA receptors [<xref ref-type="bibr" rid="CR31">31</xref>] and VGCCs [<xref ref-type="bibr" rid="CR32">32</xref>], <italic>NRXN1</italic> also encodes short NRXN1β isoforms by an alternative promoter, which is largely associated with creation of the scaffolding for excitation [<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref>]. <italic>NRXN1α</italic> is therefore proposed to influence E/I balance in both directions, whereas <italic>NRXN1β</italic> primarily mediates excitation. Indeed, conditional knockdown of <italic>NRXN1β</italic> severely impaired the neurotransmitter release at excitatory synapses [<xref ref-type="bibr" rid="CR36">36</xref>]. It is likely that NRXN1<italic>α</italic> deletion may display increased neuronal excitability, as a result of reduced ratio of <italic>NRXN1α</italic> to <italic>NRXN1β</italic> isoforms, and/or a compensatory increase of <italic>NRXN1β</italic> expression if it happens. Pak et al. showed a reduced mEPSC frequency in human ESC-derived neurons after disrupting shared exon 19 or 24 of <italic>NRXN1</italic> gene, which knocked out an entire <italic>NRXN1</italic> allele with all <italic>NRXN1α/β</italic> isoforms [<xref ref-type="bibr" rid="CR37">37</xref>]. However, this is different from the genetics in the majority of patients who carry heterozygous deletion at 5′ of <italic>NRXN1</italic> gene which affect <italic>NRXN1α</italic> only, and to date, there have been no patient models to investigate the effects of isoform deletion and/or genetic background. Moreover, it has been shown that common pathophysiological social and cognitive deficits in autism can be linked to gain of function of synaptic proteins and ion channels [<xref ref-type="bibr" rid="CR7">7</xref>]. These include hyperactivity in frontal brain regions, high-frequency oscillation in cortical regions, and the presence of clinically apparent seizures in 30% of autistic individuals [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR42">42</xref>]. In addition, mutation in neuronal adhesion molecule <italic>CNTN5</italic> has also shown hyper-excitability and increased excitation in iPSC-derived neurons of ASD individuals [<xref ref-type="bibr" rid="CR43">43</xref>]. These studies show the presence of hyper-excitability and hyperactivity in some of the ASD patients.</p>
<p id="Par14">The iPSC technology now offers significant benefits for disease modeling [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR46">46</xref>], which can be derived from patient somatic tissues. They resemble embryonic stem (ES) cells and can be differentiated into disease cell types, so to provide human models for investigating disease progression and testing therapeutic drugs, in particular for organs such as the brain and heart, which are impossible to culture by conventional methods. We therefore derived iPSCs from controls and ASD patients carrying <italic>NRXN1</italic>α<sup>+/−</sup> and differentiated them into cortical excitatory neurons, as altered cortical regions, thickness, folding, surface, columnar lamination, and the number excitatory neurons have been reported in ASD [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR51">51</xref>]. We investigated Ca<sup>2+</sup> signaling and the transcriptome in day 100 neurons and provided novel phenotype with increased Ca<sup>2+</sup> transients and upregulated VGCCs in ASD <italic>NRXN1α</italic><sup>+/−</sup> neurons.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Participants</title>
<p id="Par15">Ethical approval for the study was obtained from the St. James’s/Tallaght University Hospital and the Galway University Hospital Clinical Research Ethics Committee. Seven control iPSC lines were derived from five healthy donors (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S1). The sample 1C was donated by a healthy sibling of patient ND1, the 4C (male), the 2V (female), and the 3V (male) by healthy volunteers. The NCRM1 control line was derived by NIH from a newborn boy.</p>
<p id="Par16">All patients had confirmed research diagnoses of ASD with the Autism Diagnostic Interview-Revised and the Autism Diagnostic Observational Schedule (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S1) [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Six <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> iPSC lines were generated from three ASD patients (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1A). The ND1 was donated by a non-verbal male with severe intellectual disability, autism, infant seizures, developmental delay, self-injurious and aggressive behavior, and carrying de novo <italic>NRXN1α</italic>
<sup><italic>+/−</italic></sup> deletion on exons 6–15 (chr2:50711687-51044633, Hg19). The ND2 was a male patient carrying <italic>NRXN1α</italic>
<sup><italic>+/−</italic></sup> deletion in exons 1–5 (Chr2:51120335-51360666, Hg19), with autism, language delay, IQ of 78 at age 11, but attended mainstream education. One of ND2’s parents had language delay, and one grandfather and one cousin had ASD. The ND4-1 female was diagnosed with Asperger’s syndrome, social anxiety, psychosis, and mild intellectual disability, with an IQ of 69, a history of seizures, and a paternal <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> lesion (chr2:50983186-51471321). Her paternal grandmother was institutionalized, and her father and paternal aunt had seizures.</p>
<p id="Par17">Genomic DNA from parental fibroblasts and iPSC lines was extracted with DNeasy kit (69504, Qiagen). An Illumina 1M SNP array was performed at UCD. All samples passed quality control with call rates &gt; 99%. CNV analysis was carried out using PennCNV. False-positive CNVs were excluded using SNP &lt; 10 or kb &lt; 100. The <italic>NRXN1α</italic> deletions were confirmed (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1A), and additional putative CNVs detected are listed in Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S7.</p>
</sec>
<sec id="Sec4">
<title>iPSC derivation</title>
<p id="Par18">Skin punches were obtained with consent in the Clinical Research Facility. Biopsy was cut, dragged along the rough surface of culture dishes for adherent culture at 37 °C with 5% CO<sub>2</sub> in high glucose DMEM supplemented with 10% FCS, 1% NEAA, and 1% penicillin/streptomycin. The medium was renewed every 2–3 days. Low passage fibroblasts were reprogrammed to iPSCs (Merck-Millipore, SCR510; Thermo Fisher Scientific, or Epi5™ Episomal iPSC Reprogramming Kit; Invitrogen, A15960) and characterized for expression of alkaline phosphatase, NANOG, OCT4, SOX2, SSEA4, TRA-1-60, TRA-1-81, TUJ1, ASM, and AFP.</p>
</sec>
<sec id="Sec5">
<title>Neuronal differentiation</title>
<p id="Par19">The iPSCs were seeded at 45,000–50,000 cells/cm<sup>2</sup>, grown to ~ 85% confluency in E8 (Thermo Fisher Scientific, A1517001), and differentiated into neural rosettes for 10–12 days in N2B27 (Thermo Fisher Scientific) with 100 nM LDN193189 (Stem Cell technologies, #72102) and 10 nM SB431542 (Sigma, S4317) [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Neural rosettes were passaged, cultured for another 10 days, and then plated onto poly-D-Lysine/laminin-coated 12-well plates, 15-mm coverslips, or ibidi 8-well chambers for terminal differentiation. Cells were maintained in N2B27 (w/o vitamin A) for 6 days and then in N2B27 plus vitamin A until analyses by immunocytochemistry, immunoblotting, calcium imaging, or RNA sequencing, respectively. All phenotypic analyses were performed at day 100 of differentiation according to previous published protocol [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
</sec>
<sec id="Sec6">
<title>Immunocytochemistry</title>
<p id="Par20">Cells were fixed in 4% paraformaldehyde, blocked with 0.2% BSA, and incubated with primary antibodies (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S8) at 4 °C overnight. They were washed, incubated for 1 h at room temperature with appropriate secondary antibody (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S8), and mounted with DAPI. Images were taken under a fluorescence microscope and quantified by ImageJ.</p>
</sec>
<sec id="Sec7">
<title>Calcium imaging</title>
<p id="Par21">Cultures were washed with artificial cerebrospinal fluid (ACSF), incubated with 2 μM Fluo-4 AM (Thermo Fisher scientific, F14201) in ACSF for 20 min at 37 °C, cultured in normal medium at 37 °C for 20 min, and imaged in warm ACSF in an imaging chamber (Warner Instruments, RC-26GLP) on a Zeiss Axiovert 200 microscope (× 10). Videos were captured with a Hamamatsu ORCA284 at 1 Hz frame rate for 3–5 min and stored as uncompressed image sequences.</p>
<p id="Par22">Chemicals were added to the ACSF as required, i.e., Na<sup>+</sup> channel blocker TTX (Alomone Labs T-550), AMPA/Kainate receptor blocker CNQX (Alomone Labs C-140), NMDA receptor blocker DL-AP5 (Alomone Labs D-140), L-type VGCC blocker Nifedipine (Alomone Labs N-120), P/Q-type VGCC blocker agatoxin (Alomone Labs STA-500), glutamate (Sigma, G8415), ionomycin (Sigma I0634), or γ-aminobutyric acid (Sigma A2129). Videos were recorded continuously.</p>
<p id="Par23">FluoroSNNAP in MATLAB (MathWorks, Inc.) was used to analyze calcium image sequences [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Neurons with &gt; 5% fluorescence variations during recording were identified by time-lapse analysis and cell soma defined using batch segmentation. A time-varying fluorescence trace was calculated, transient onset identified, and background noise (ΔF/F &lt; 0.05) determined. The frequency, amplitude, duration, and network synchronicity of spontaneous and evoked calcium transients were analyzed by a coding script in R software.</p>
</sec>
<sec id="Sec8">
<title>Quantitative RT-PCR</title>
<p id="Par24">RNA was extracted (Qiagen, 74104) and reversely transcribed (Qiagen, 205311). RT-PCR was executed in triplicate with primers listed in Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S9. The average cycle threshold (Ct) values were calculated in both control and <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> lines from three technical replicates. All Ct values were normalized to expression of a house-keeping gene (<italic>GAPDH</italic>) as dCt. Relative expression was expressed as 2<sup>–dCt</sup> over <italic>GAPDH</italic> expression or 2<sup>–ddCt</sup> over the target gene expression in control fibroblasts for iPSC characterization.</p>
</sec>
<sec id="Sec9">
<title>Transcriptomic analysis</title>
<p id="Par25">RNASeq was performed by BGI as described previously [<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR57">57</xref>] on day 100 cortical neurons from six control iPSC lines of four donors and four <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> lines of three patients. Transcripts were aligned to GRCH37/hg19, and abundance quantified from the FASTQ in Kallisto (v0.43.1) and presented as transcripts per million (TPM). The two groups were analyzed with false discovery rate (FDR) and adjusted multiple <italic>p</italic> value using the DESeq2 in R. PLS discriminant analysis (PLS-DA) was carried out for supervised clustering, confirming the close clustering among controls and patients. PLS-DA is a supervised method for pattern recognition of unsupervised PCA data and uses the partial least squares (PLS) algorithm to explain and predict the membership of observations to several classes using quantitative or qualitative explanatory variables or parameters [<xref ref-type="bibr" rid="CR58">58</xref>]. Differentially expressed genes (DEGs) were identified using FDR &lt; 0.05, TPM &gt; 2, &gt; 50% reduction, or &gt; 1.7-fold increase based on TPM ratio and analyzed by STRING and Gene Set Enrichment Analysis (GSEA).</p>
</sec>
<sec id="Sec10">
<title>Statistics</title>
<p id="Par26">All data were expressed as mean ± SEM. All data were tested for normality using the Shapiro-Wilk normality test. Statistical analysis was performed using the Student <italic>t</italic> test or Mann-Whitney <italic>U</italic> test with a <italic>p</italic> &lt; 0.05.</p>
</sec>
</sec>
<sec id="Sec11">
<title>Results</title>
<sec id="Sec12">
<title>Derivation of iPSCs</title>
<p id="Par27">In this study, we compared six <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> iPSC lines from three ASD cases [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>] with six iPSC lines from five healthy controls (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S1). The mutations were validated by SNP array (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1A). iPSCs were derived from dermal fibroblasts (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a–c) and characterized for pluripotency by expression of alkaline phosphatase (Fig. <xref ref-type="fig" rid="Fig1">1</xref>d), NANOG, OCT4, SOX2, SSEA4, and TRA-1-60 (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S2) and tri-germ layer potential by TUJ1, ASM, and AFP (Fig. <xref ref-type="fig" rid="Fig1">1</xref>d–j, n, o) and cell cycle markers Ki67 and PH3 (Fig. <xref ref-type="fig" rid="Fig1">1</xref>k–m).
<fig id="Fig1"><label>Fig. 1</label><caption><p>Derivation and validation of iPSCs. <bold>a</bold> Fibroblast outgrowth from the skin biopsy after 12 days of culturing. <bold>b</bold> IPSC colonies were visible and ready for collection after 24 days of reprogramming and became stable after few passaging (<bold>c</bold>). iPSCs were characterized and were stained positive for alkaline phosphatase (<bold>d</bold>) and pluripotent markers OCT4, SOX2, and NANOG and surface markers SSEA4 and TRA-1-60 and TRA-1-81 (<bold>b</bold>–<bold>g</bold>). Spontaneous EB differentiation has shown the expression of markers for mesoderm (ASM, <bold>h</bold>), ectoderm (TUJ1, <bold>i</bold>), and endoderm (AFP, <bold>j</bold>). iPSCs also showed positive expression of proliferating marker Ki67 (<bold>k</bold>) and (<bold>m</bold>) phase marker PH3 (<bold>l</bold>). They were also quantified at mRNA level for the expression of <italic>OCT4</italic> (<bold>n</bold>) and <italic>SOX2</italic> (<bold>o</bold>). All representative images all from control line 4CCX1</p></caption><graphic id="MO1" xlink:href="13229_2019_303_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec13">
<title>Differentiation of cortical excitatory neurons</title>
<p id="Par28">We differentiated iPSCs to cortical excitatory neurons using dual SMAD inhibition with LDN193189 and SB431542 [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>], and this was accompanied by formation of neural rosettes at 10–12 days, downregulation of <italic>OCT4</italic>, and upregulation of a neural fate marker <italic>PAX6</italic> (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S3A and B). At day 20, 87% of cells were Nestin<sup>+</sup> and 82% PAX6<sup>+</sup> (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S3D-F). High levels of expression of <italic>PAX6</italic>, <italic>NES</italic>, <italic>FOXG1</italic>, and <italic>NEUROG2</italic> mRNA demonstrated that they were cortical progenitors (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S3C).</p>
<p id="Par29">In day 100 cultures of directional differentiation, we compared MAP2<sup>+</sup> neurons with GFAP<sup>+</sup> astrocytes and confirmed that the majority of cells were neurons with few astrocytes (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S4B, C), in consistency with the previous publication [<xref ref-type="bibr" rid="CR53">53</xref>]. There was no significant difference in proportions of MAP2<sup>+</sup> or GFAP<sup>+</sup> cells between the controls and <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> samples, which is different from random differentiation of total <italic>NRXN1</italic> (α and β) knockdown in stem cells (Zeng et al. 2013). The neuronal maturity and synapses were confirmed by positive staining of MAP2/SYN1/TUJ1 (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a, b). There was no significant difference in synaptic density and as comparable expression of <italic>MAP2</italic> or <italic>SYN1</italic> mRNA and protein was found in two groups (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S4A, D). In the day 100 culture, 23.4% of cells were layer VI cortical neurons which were positive for TBR1, and 36.2% of cells were layer V-VI neurons expressing CTIP2. RT-PCR showed also equally abundant expression of <italic>BRN2/SATB2</italic> mRNA, the markers for upper-layer neurons. Therefore, the majority of cells were cortical projection neurons (Fig. <xref ref-type="fig" rid="Fig2">2</xref>c–e). We examined <italic>NRXN1α</italic> expression by using two pairs of primers derived from exons 9–10 and exons 15–16, respectively, and found 24 or 26% of reduction. Meanwhile, <italic>NRXN1β</italic> expression was increased by 262% as a compensational change (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S7). However, <italic>NRXN2</italic> and <italic>NRXN3</italic> expressions remain unaltered.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Differentiation and validation of the cortical excitation neurons. <bold>a</bold>–<bold>c</bold> ICC staining of day-100 neurons with MAP2 (<bold>a</bold>), SYN1/TUJ1 (<bold>b</bold>) for neuronal maturity, and with TBR1/CTIP2 for the identity of lower cortical pyramidal neurons (<bold>c</bold>). <bold>d</bold> Proportion of layer VI (TBR1<sup>+</sup>) and layer V/VI (CTIP2<sup>+</sup>) neurons in the cultures. <bold>e</bold> High mRNA expression (normalized to GAPDH [dotted line]) of excitatory post-synaptic markers (<italic>DLG4</italic>, <italic>SHANK1</italic>, <italic>SHANK2</italic>, <italic>SHANK3</italic>, <italic>SLC17A7</italic>, <italic>GRIN1</italic>, <italic>GRIN2A</italic>, <italic>GRIA1</italic>, <italic>GRIA4</italic>, <italic>GRIK1</italic>, <italic>GRIK3</italic>), neuronal markers (<italic>TUBB3</italic>, <italic>MAP2</italic>), upper cortical layers (<italic>BRN2</italic>, <italic>SATB2</italic>), and lower layer markers (<italic>TBR1</italic>, <italic>CTIP2</italic>) in day-100 cultures of control (black) and <italic>NRXN1α</italic><sup>+/−</sup> (red) neurons. Results shown from two independent cortical neuronal differentiation (<bold>f</bold>). Representative waterfall traces of spontaneous Ca<sup>2+</sup> transients in day 50 (blue) and 100 (pink) cultures from 200 s of recording. Neurons exhibited a significant increase in proportion (%) of spontaneous active cells (<bold>g</bold>), the frequency (mHz, <bold>h</bold>), and the amplitude (ΔF/F, <bold>i</bold>) of Ca<sup>2+</sup> transients from day 50 to day 100. Statistical significance (**<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001, ****<italic>p</italic> &lt; 0.0001) was evaluated using the Mann-Whitney <italic>U</italic> test). All representative images all from control line 4CCX1</p></caption><graphic id="MO2" xlink:href="13229_2019_303_Fig2_HTML"></graphic></fig></p>
<p id="Par30">High level of postsynaptic excitatory markers (<italic>DLG4</italic>, <italic>SHANK1-3</italic>), vesicular glutamate transporter (<italic>SLC17A7</italic>), inotropic NMDA (<italic>GRIN1</italic>, <italic>GRIN2A</italic>), AMPA (<italic>GRIA1</italic>, <italic>GRIA4</italic>), and Kainate (<italic>GRIK1</italic>, <italic>GRIK3</italic>) receptor mRNA were detected by qRT-PCR (Fig. <xref ref-type="fig" rid="Fig2">2</xref>e). RNASeq confirmed extremely low levels of GABAergic (<italic>GABRA1</italic>, <italic>GABRA6</italic>, <italic>GABRD</italic>, <italic>GABRE</italic>, <italic>GABRG3</italic>, <italic>GABRP</italic>, <italic>GABRR1</italic>, and <italic>GABRR2</italic>) gene expression in comparison with excitatory genes (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S5). In addition, GABA (60 μM) elevated Ca<sup>2+</sup> active cells only by 2.3%, whereas glutamate (60 μM) increased the number of Ca<sup>2+</sup> active cells by 82.3% (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S6A, B). These data together demonstrated that the majority of day-100 cells in culture were cortical and excitatory neurons.</p>
</sec>
<sec id="Sec14">
<title>Voltage-dependent Ca<sup>2+</sup> transients</title>
<p id="Par31">We next validated neuronal functionality by Ca<sup>2+</sup> imaging (Fig. <xref ref-type="fig" rid="Fig2">2</xref>f). The proportion, frequency, and amplitude of spontaneous Ca<sup>2+</sup> transients were significantly increased from day 50 to 100 (Fig. <xref ref-type="fig" rid="Fig2">2</xref>g–i), suggesting that the culture system supported continuous maturation. As the dynamics of calcium signaling can modulate E/I balance through gene regulation and action potential-dependent neurotransmitter release, we analyzed spontaneous Ca<sup>2+</sup> transient properties in day 100 neurons. The Ca<sup>2+</sup> transients were shown to be voltage-gated and Na<sup>+</sup> channel-dependent, as TTX (1 μM) abolished 88% of Ca<sup>2+</sup> transients (Fig. <xref ref-type="fig" rid="Fig3">3</xref>e). DL-AP5 and CNQX reduced Ca<sup>2+</sup> transients by 98.3% and 61.2%, respectively, suggesting most cells expressed NMDA/AMPA/Kainate receptors (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a, b). Nifedipine and agatoxin decreased the number of active cells by 67.3% or 84.0%, suggesting both L- and P/Q-types of VGCCs co-existed in the cultures (Fig. <xref ref-type="fig" rid="Fig3">3</xref>c, d). Nifedipine, agatoxin, CNQX, and glutamate showed similar effects on spontaneous calcium transients in <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S6C). Therefore, spontaneous Ca<sup>2+</sup> transients in day-100 excitatory neurons are associated with membrane depolarizations (inhibited by TTX) and are facilitated by VGCC (inhibited by nifedipine and agatoxin).
<fig id="Fig3"><label>Fig. 3</label><caption><p>Spontaneous calcium transients are voltage-gated calcium, action potential, and excitatory dependent. <bold>a</bold> Representative raster plots (activity of 100 cells in 300 s of recording, each dot represents Ca<sup>2+</sup> transient activity, Line 4CX1), waterfall traces (3D representative of calcium transients in 300 s over defined threshold level, Line 4CX1), and their significant change showing the spontaneous Ca<sup>2+</sup> transient activity of the cells and their response after the application of DL-AP5 (50 μM, <bold>a</bold>) and CNQX (50 μM, <bold>b</bold>), Nifedipine (50 μM, <bold>c</bold>), agatoxin (500 nM, <bold>d</bold>), and TTX (1 μM, <bold>e</bold>) (<italic>n</italic> = 2–3, 1CC1, 3VCX1, 4CX1). The red dotted line shows the point of drug application. All data summary are mean ± SEM</p></caption><graphic id="MO3" xlink:href="13229_2019_303_Fig3_HTML"></graphic></fig></p>
</sec>
<sec id="Sec15">
<title><italic>NRXN1α</italic><sup><italic>+/−</italic></sup> deletion altered the kinetics of spontaneous Ca<sup>2+</sup> transients</title>
<p id="Par32">We subsequently compared Ca<sup>2+</sup> transient characteristics in 34,746 control neurons and 19,261 <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons (Fig. <xref ref-type="fig" rid="Fig4">4</xref>a–f) (Additional file<xref ref-type="media" rid="MOESM1">1</xref>: Figure S8). The regions of interest (neurons) were quantified by batch segmentation within FluoroSNNAP. The proportion of spontaneous active cells was not significantly different between the two groups (control 33.95 ± 2.9%, patient 34.9 ± 2.8%, <italic>p</italic> = 0.92; Fig. <xref ref-type="fig" rid="Fig4">4</xref>g). However, the frequency of Ca<sup>2+</sup> transients was increased by 30.8% in <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons (11.72 ± 0.7 mHz, <italic>p</italic> &lt; 0.0001) compared to controls (7.91 ± 0.3 mHz, Fig. <xref ref-type="fig" rid="Fig4">4</xref>c–f, h). Additionally, the duration of the Ca<sup>2+</sup> transients was significantly prolonged in <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons (7.10 ± 0.3 s, <italic>p</italic> = 0.038) versus controls (6.30 ± 0.2 s, Fig. <xref ref-type="fig" rid="Fig4">4</xref>i). The amplitude of Ca<sup>2+</sup> transients was also significantly elevated from controls (0.098 ± 0.003 ΔF/F, Fig. <xref ref-type="fig" rid="Fig4">4</xref>j) to <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons (0.123 ± 0.014 ΔF/F, <italic>p</italic> = 0.008). Therefore, <italic>NRXN1α</italic> deletion significantly altered Ca<sup>2+</sup> transient characteristics in iPSC-derived cortical excitatory neurons. In addition, all probands were separately investigated against any available family control (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S9) or all controls (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S10). The effect of history of seizures in two probands (ND1, ND4) was also measured in comparison with ND2 (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S11). ASD patient samples showed consistent changes in the frequency of Ca<sup>2+</sup> transients (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S10, S11).
<fig id="Fig4"><label>Fig. 4</label><caption><p>Spontaneous Ca<sup>2+</sup> transient properties were significantly altered in the day 100 <italic>NRXN1α</italic>
<sup>+/−</sup> neurons. <bold>a</bold>, <bold>b</bold> The representative images of control (<bold>a</bold>) and patient (<bold>b</bold>) cells loaded with Fluo-4 AM, displaying dense network of neurons in day 100 neuronal cultures. <bold>c</bold>, <bold>d</bold> Representative raster plots showed the spontaneous Ca<sup>2+</sup> transient activity of the cells from control (<bold>c</bold>) and patient (<bold>d</bold>) cultures. <bold>e</bold>, <bold>f</bold> Representative waterfall traces of spontaneous Ca<sup>2+</sup> transients in 250 cells over 300 s of recording. <bold>g</bold> The percentage of spontaneous Ca<sup>2+</sup> transients remained unchanged between the two groups. <bold>h</bold> The frequency of spontaneous Ca<sup>2+</sup> transients was significantly increased in the <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> deletion patient cells. <bold>i</bold> The duration of calcium transients was significantly longer in the <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> deletion patient cells. <bold>j</bold> The amplitude of spontaneous Ca<sup>2+</sup> transient was significantly increased in the <italic>NRXN1α</italic><sup><italic>+/</italic></sup> deletion patient cells. Control <italic>n</italic> = 74 recordings/26 coverslips from 6 control iPSC lines (patient <italic>n</italic> = 47 recordings/21 coverslips) from 6 <italic>NRXN1α</italic>
<sup>+/−</sup> iPSC lines (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S10). All data summary are mean ± SEM. Statistical significance (**<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001, ****<italic>p</italic> &lt; 0.0001) was evaluated using the Mann-Whitney <italic>U</italic> test. Bar = 100 μm in <bold>a</bold>, <bold>b</bold>. Representative images are from control line 4CCX1 and patient ND1C1</p></caption><graphic id="MO4" xlink:href="13229_2019_303_Fig4_HTML"></graphic></fig></p>
<p id="Par33">To address potential variability, we applied separate transformations to the parameters of “amplitude,” “duration,” and “frequency” of Ca<sup>2+</sup> transients, as our data were non-parametric. We next carried out multivariant analysis of variance (MANOVA) between <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> and control groups and validated a significant difference between the two groups (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S2A). Subsequently, we used two-way nested ANOVA to test each variable on the transformed data, which demonstrated significant differences for “amplitude,” “duration,” or “frequency” between the two groups (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S2B).</p>
</sec>
<sec id="Sec16">
<title>VGCC pathway was disrupted in <italic>NRXN1α</italic><sup>+/−</sup> neurons</title>
<p id="Par34">To explore the molecular pathways associated with <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> ASD neurons, we performed whole-genome RNASeq in day-100 neurons from six controls and four <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> lines. A total of 27,163 transcripts were quantitatively sequenced and 530 differentially expressed genes (DEGs) identified, with 254 downregulated and 276 upregulated genes (Fig. <xref ref-type="fig" rid="Fig5">5</xref>a, b, Additional file <xref ref-type="media" rid="MOESM1">1</xref> Table S3). PLS discriminant analysis (PLS-DA) was carried out for supervised clustering, confirming the close clustering among controls and patients (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S12A). In addition, the expression of DEGs among control and patient iPSC-derived neurons is shown to be consistent (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S12B).
<fig id="Fig5"><label>Fig. 5</label><caption><p>The pathways of calcium and ion transport activity were significantly enriched in <italic>NRXN1α</italic><sup><bold><italic>+/−</italic></bold></sup> iPSC-derived neurons. <bold>a</bold> Volcano plot of FDR on the <italic>y</italic>-axis and Log<sub>2</sub> fold changes on the <italic>x</italic>-axis of DEGs in <italic>NRXN1α</italic><sup>+/−</sup> neurons. Among the 530 DEGs, 254 were downregulated (in green) and 276 upregulated (in red) with FDR &lt; 0.05. <bold>b</bold> Bivariate clustering of samples (columns) of the 530 DEGs. The color ranges from purple (low expression) to yellow (high expression) based on TPM values (<ext-link ext-link-type="uri" xlink:href="http://rpubs.com/saharava/BivariateClustering">http://rpubs.com/saharava/BivariateClustering</ext-link>). The arrows represent the up/downregulated genes in <italic>NRXN1α</italic><sup>+/−</sup> neurons. <bold>c</bold> The heatmap represented all genes which were linked to the 21 pathways. The color showed the most overlapped genes in dark red to non-overlapped genes in white among the pathways. <bold>d</bold> Upregulated (right) and downregulated (left) genes were shown with Log<sub>2</sub> fold expression. The VGCCs of <italic>CACNA1A</italic>, <italic>CACNA2D1</italic>, and <italic>CACNG2/3</italic> were shared by most pathways</p></caption><graphic id="MO5" xlink:href="13229_2019_303_Fig5_HTML"></graphic></fig></p>
<p id="Par35">STRING and GSEA analyses revealed impairments in calcium binding (GO.0005509, FDR = 7.30E−06), ion transport (GO.0006816, FDR = 7.78E−03), transporter activity (GO.0015085, FDR = 4.92E−02), and voltage-gated channel complexes (GO.0005891, FDR = 2.65E−02) in <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S4). Four VGCC genes, <italic>CACNA1A</italic> (encoding P/Q-type), <italic>CACNA2D1</italic> (encoding L-type), <italic>CACNG2</italic>, and <italic>CACNG3</italic> (encoding auxiliary subunits), were among the most enriched targets in functional pathways (Fig. <xref ref-type="fig" rid="Fig5">5</xref>c, Fig. <xref ref-type="fig" rid="Fig6">6</xref>a) and were upregulated by 2.02, 1.90, 2.13, and 3.29-fold (Fig. <xref ref-type="fig" rid="Fig5">5</xref>d), respectively. Among the 530 targets, <italic>CACNA1A</italic> was identified as the most overlapped gene among the top 20 pathways (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S13). Subsequent STRING analyses of downregulated or upregulated DEGs, respectively, demonstrated exclusive association of calcium signaling pathways with the upregulated (not downregulated) DEGs (Fig. <xref ref-type="fig" rid="Fig6">6</xref>b, Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S5). Taken together, both functional and transcriptome analyses suggest an increase in calcium signaling pathways as a major phenotype in the <italic>NRXN1α</italic><sup>+/−</sup> ASD neurons.
<fig id="Fig6"><label>Fig. 6</label><caption><p>Strong association of calcium channel activity in <italic>NRXN1α</italic><sup><bold><italic>+/−</italic></bold></sup> iPSC-derived neurons. <bold>a</bold> String KEGG analyses showing a significant network of VGCC association. Proteins in red are associated with calcium ion binding, in blue nodes with calcium ion transmembrane transporter activity, in green node with calcium channel activity, in yellow with voltage-gated calcium channel activity, and in purple with calcium signaling pathway. <bold>b</bold> STRING analyses of upregulated (not downregulated) genes in the <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons showed association with “calcium ion transport” (red, 12 genes, FDR + 3.20E−03), “calcium ion transmembrane transport” (blue, 9 genes, FDR = 2.06E−02), “voltage-gated calcium channel activity” (green, 6 genes, FDR5.50E−04), calcium signaling pathway (pink, 8 genes, FDR = 4.89E−02), and “presynaptic depolarization and calcium channel opening” (light blue, 3 genes, FDR = 2.37E−02)</p></caption><graphic id="MO6" xlink:href="13229_2019_303_Fig6_HTML"></graphic></fig></p>
</sec>
</sec>
<sec id="Sec17">
<title>Discussion</title>
<p id="Par36"><italic>NRXN1</italic><sup><italic>+/−</italic></sup> deletions are the most frequent single-gene disruptions associated with ASD [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], schizophrenia [<xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR20">20</xref>], intellectual disability [<xref ref-type="bibr" rid="CR21">21</xref>], ADHD [<xref ref-type="bibr" rid="CR22">22</xref>], and epilepsy [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR26">26</xref>]. Little is known about the consequences of <italic>NRXN1</italic><sup>+/−</sup> lesions in patients’ neurons or why the same heterozygous <italic>NRXN1</italic><sup>+/−</sup> deletions lead to diverse clinical phenotypes. We are the first to report derivation of human iPSCs from ASD patients carrying <italic>NRXN1α</italic><sup><italic>+/−</italic></sup>. The cortical excitatory neurons from <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> iPSCs displayed a novel phenotype of increased frequency, duration, and amplitude of Ca<sup>2+</sup> transients. This is supported by transcriptome analyses, which revealed an upregulation of VGCCs (<italic>CACNA1A</italic>, <italic>CACNA2D1</italic>, <italic>CACNG2</italic>, and <italic>CACNG3</italic>) and Ca<sup>2+</sup> pathways in <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons.</p>
<p id="Par37">Typically in neurons, calcium influx is facilitated by the opening of the α1 subunit in the tetrameric VGCCs in response to membrane depolarizations. The α1 subunit is encoded by <italic>CACNA1A</italic>, <italic>CACNA1B</italic>, <italic>CACNA1C</italic>, <italic>CACNA1D</italic>, <italic>CACNA1E</italic>, and <italic>CACNA1S</italic> genes. Consistent with ASD <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> phenotype, gain-of-function of VGCCs are implicated in neurodevelopmental disorders (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S6). For example, Cav1.2 G406R (<italic>CACNA1C</italic>) causes Timothy syndrome with ASD by delayed inactivation and prolonged opening [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Knock-in of the G406R to mice results in autistic phenotype [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Exome sequencing has identified various <italic>CACNA1D</italic> mutations (encoding Cav1.3) in ASD [<xref ref-type="bibr" rid="CR63">63</xref>–<xref ref-type="bibr" rid="CR66">66</xref>], epilepsy [<xref ref-type="bibr" rid="CR67">67</xref>], and developmental delay [<xref ref-type="bibr" rid="CR67">67</xref>]. A <italic>CACNA1D</italic> paralog, <italic>CACNA1F</italic> (Cav1.4), also is linked to New Zealand autistic males with excessive Ca<sup>2+</sup> influx [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>].</p>
<p id="Par38">We have identified <italic>CACNA1A</italic> encoding P/Q-type and <italic>CACNA2D1</italic> encoding L-type VGCC as the most interactive <italic>NRXN1α</italic><sup>+/−</sup> targets. <italic>CACNA1A</italic> is predominantly expressed in neurons and involved in NRXN1α signaling which triggers the release of fusion-ready vesicles [<xref ref-type="bibr" rid="CR68">68</xref>]. <italic>CACNA1A</italic> polymorphisms are associated with Chinese ASD [<xref ref-type="bibr" rid="CR68">68</xref>], and <italic>CACNA1A</italic> mutations with epileptic encephalopathy [<xref ref-type="bibr" rid="CR68">68</xref>]. Additionally, mutations in other VGCCs are also identified as a major pathway in schizophrenia [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>], the common risks across seven brain diseases [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>], and in ASD (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S6) [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. In addition, loss-of-function mutations in some VGCCs are also reported, i.e., <italic>CACNA1H</italic> R212C, R902W, W962C, and A1874V reduce their activity in ASD [<xref ref-type="bibr" rid="CR74">74</xref>]; <italic>CACNA2D1</italic> is deleted in epilepsy and intellectual disability [<xref ref-type="bibr" rid="CR74">74</xref>]; <italic>CACNG2</italic> V143L decreases its binding to GLUR1 or GLUR2 [<xref ref-type="bibr" rid="CR75">75</xref>]; and <italic>Cacng2</italic> hypomorph results in epileptic phenotype [<xref ref-type="bibr" rid="CR74">74</xref>]. This evidence supports altered VGCCs as a mechanism in ASD <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons.</p>
<p id="Par39">The human <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> phenotype reported here differs from some of the data reported previously. Pak et al. created a mutant human H1 ES cell line with disruption of exon 19 or 24, which are shared by all <italic>NRXN1</italic> isoforms (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1A), and showed reduced frequency of mEPSCs [<xref ref-type="bibr" rid="CR37">37</xref>]. <italic>NRXN1</italic> consists of 2 promoters and 11 differentially spliced exons which may result in 2048 <italic>NRXN1α</italic> and 4 <italic>NRXN1β</italic> isoforms. The human H1 ES cells (<italic>NRXN1</italic><sup>+/−</sup>) from Pak et al. are genetically different from the ASD patients here, who carry 1 copy of <italic>NRXN1α</italic><sup>+/−</sup>. However, qRT-PCR using primer pairs from exons 9–10 or 15–16 demonstrate 24 or 26% (not 50%) reduction. This is likely due to the complex exon usage of differential NRXN1 splicing. Meanwhile, we observe 262% compensational increase in <italic>NRXN1β</italic> expression; therefore, the phenotype in this study is likely to result from combinational effects of reduced <italic>NRXN1α</italic> and overexpression of <italic>NRXN1β</italic>. This may also re-enforce the concept that <italic>NRXN1α</italic> and <italic>NRXN1β</italic> isoforms play differential roles in neuronal E/I.</p>
<p id="Par40">Sudhoff et al. propose that Neurexin variants from alternative splicing may perform the same canonical functions but may have different patterns of redundancy [<xref ref-type="bibr" rid="CR76">76</xref>–<xref ref-type="bibr" rid="CR78">78</xref>]. <italic>Nrxn1α</italic> homozygous knockout presented no apparent phenotype, and Pak et al. also showed that mouse <italic>Nrxn1</italic> knockout cells differed from H1 ES cells and displayed no phenotype [<xref ref-type="bibr" rid="CR79">79</xref>]. Mice with triple knockout of <italic>Nrxn1α</italic>, <italic>Nrxn2α</italic> and <italic>Nrxn3α</italic> genes were shown to produce different phenotypes in different neurons or synapses [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. In hippocampal presynaptic cells, the Ca<sup>2+</sup> influx was reduced in conjunction with lower Cav2.1-mediated transients and elevated axonal mobility of α2δ1 [<xref ref-type="bibr" rid="CR80">80</xref>]. Although overexpression of <italic>Nrxn1α</italic> and α2δ1 is shown to rescue Ca<sup>2+</sup> currents in <italic>Nrxn1α</italic><sup><italic>−/−</italic></sup><italic>Nrxn2α</italic><sup><italic>−/−</italic></sup><italic>Nrxn3α</italic><sup><italic>−/−</italic></sup> triple knockout mouse neurons, this is yet to be investigated in human cells [<xref ref-type="bibr" rid="CR80">80</xref>]. In addition, species differences also exist: i.e., Nrxn1 at <italic>Caenorhabditis elegans</italic> acetylcholine neuromuscular synapse is located postsynaptically, not presynaptically [<xref ref-type="bibr" rid="CR32">32</xref>], and approximately &gt; 20% of human essential genes are nonessential in mice [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
<p id="Par41">The penetrance of human <italic>NRXN1a</italic><sup><italic>+/−</italic></sup> is not 100%, and clinical conditions of <italic>NRXN1a</italic><sup><italic>+/−</italic></sup> are diverse. Therefore, co-factors in the genetic background may play a part in clinical phenotype. Investigations of patient-derived samples are essential for understanding roles of <italic>NRXN1a</italic><sup><italic>+/−</italic></sup> in different human conditions. The ASD <italic>NRXN1a</italic><sup><italic>+/−</italic></sup> phenotype here is consistent with the proposal that NRXN1β triggers excitation, and NRXN1α regulates both excitation and inhibition [<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref>]. <italic>NRXN1α</italic> deletions are therefore anticipated to weaken neuronal inhibition and increase excitation. A recent publication has shown that ASD neurons derived from autism CNTN5<sup>+/−</sup> or EHMT2<sup>+/−</sup> human iPSCs develop hyperactive neuronal networks [<xref ref-type="bibr" rid="CR43">43</xref>]. This suggests indirect effects of NRXN1α on Ca<sup>2+</sup> transients. The upregulated CACNA1A, CACNA2D2, and CACNG2 are linked to “the presynaptic depolarization and calcium channel opening” by STRING (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S5). Direct interactions of NRXNs with VGCCs are reported but limited. Mouse Nrxn1α is shown to positively modulate Ca<sup>2+</sup> influx through Cav2.1-α2δ1 interaction [<xref ref-type="bibr" rid="CR80">80</xref>]. On the other hand, human NRXN1α may also form NRXN1α-Cav2.2-αδ3 complex and negatively regulate Cav2.2 currents in transfected cells [<xref ref-type="bibr" rid="CR32">32</xref>]. Furthermore, Neuroligins contain Ca<sup>2+</sup>-binding EF-hand domains, and Neuroligin-NRXN1β interaction is dependent on Ca<sup>2+</sup> [<xref ref-type="bibr" rid="CR81">81</xref>]. Elevated Ca<sup>2+</sup> transients in human <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons may therefore also enhance excitation through increased Neuroligin-NRXN1β interactions. Furthermore, we have observed an increase in the expression of few members of SNARE complexes, i.e., synaptotagmins, suggesting an interaction of the cytoplasmic membrane of neurexins with synaptotagmins [<xref ref-type="bibr" rid="CR82">82</xref>]. It seems likely that NRXN1α may regulate the level of synaptotagmins or other members of SNARE proteins, which might be critical for neurotransmitter and vesicle release [<xref ref-type="bibr" rid="CR83">83</xref>]. Interestingly, two of our ASD patients had a history of seizures. While the patient numbers were small, it appeared that the increase of the frequency was more prominent in two ASD probands with seizure (ND1, ND4) than the ASD without seizure (ND2, Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S11). This concurs with disrupted Ca<sup>2+</sup> signaling implicated in a range of neurodevelopmental disorders including ASD and epilepsy [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR84">84</xref>–<xref ref-type="bibr" rid="CR88">88</xref>].</p>
<p id="Par42">The DEGs in <italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons may arise from Ca<sup>2+</sup> influx and voltage-dependent conformational changes of VGCCs. For example, Cav1.2 may interact with αCaMKII, and βCaMKII is then recruited by Ca<sup>2+</sup> mobilization. Voltage-dependent conformational changes can lead to α/βCaMKII activation, CREB phosphorylation and nuclear accumulation [<xref ref-type="bibr" rid="CR89">89</xref>], and activation of transcription factors NFAT and MEF2 [<xref ref-type="bibr" rid="CR90">90</xref>–<xref ref-type="bibr" rid="CR94">94</xref>]. Therefore, the transcriptomic changes may reflect both the activity-driven alterations and functional features of ASD <italic>NRXN1α</italic><sup>+/−</sup> neurons.</p>
</sec>
<sec id="Sec18">
<title>Limitations</title>
<p id="Par43">There are several limitations which may be addressed in the follow-up studies. (1) While we provide strong evidence for the role of VGCCs as a contributor to alterations in NRXN1α<sup>+/−</sup> neurons, in this study, we employed the non-ratiometric calcium reporter Fluo-4 AM to represent intracellular calcium dynamics in the absence of ground-truth electrophysiological recordings and direct measurements of VGCCs. Future studies will be required to directly measure the channel activation and kinetics in NRXN1α<sup>+/−</sup> neurons. (2) The NRXN1 deletions are associated with different clinical symptoms; therefore, NRXN1 deletion iPSCs from different neurodevelopmental/neuropsychiatric diseases may be investigated through collaborative research (3). The heterogeneity of iPSCs is common. Although the current data are conducted with statistically viable numbers and vigorously justified with different statistical methods, experiments with a larger cohort of iPSC lines will be desirable to confirm the commonality of the phenotype. (4) Genetic rescue will be important to validate genotype-phenotype correlation, but this is technically challenging, given that the <italic>NRXN1</italic> deletion sizes of chromosomal regions are beyond the limit of conventional rescue constructs. In addition, the NRXN1 non-coding sequences are evolutionally conserved, and NRXN1 gene expression is highly regulated; therefore, no single cDNA-based construct may be able to rescue the phenotype with the right dose, isoform, and/or developmental regulation of the NRXN1 expression. (5) As the clinical penetrance of NRXN1 deletion is incomplete, a second hit may be required for different clinical phenotypes. Creation of isogenic lines with large chromosomal deletions is under the way, albeit technically challenging. It remains to see if the isogenic lines on healthy genetic background will have the same cellular phenotype as from the ASD individuals.</p>
</sec>
<sec id="Sec19">
<title>Conclusions</title>
<p id="Par44"><italic>NRXN1α</italic><sup><italic>+/−</italic></sup> neurons derived from ASD patients’ iPSCs revealed alteration in calcium transients’ properties, leading to increased calcium activity. These findings may suggest an alteration in neurotransmitter release and a possible higher excitability in neurons. The <italic>NRXN1α</italic><sup>+/−</sup> iPSCs may be offered as a human model with translatable phenotype for drug screening and testing of ASD.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec20">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13229_2019_303_MOESM1_ESM.docx"><caption><p><bold>Additional file 1.</bold> Supplementary figures and tables.</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>ASD</term>
<def>
<p id="Par5">Autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term>E/I</term>
<def>
<p id="Par6">Excitation/inhibition</p>
</def>
</def-item>
<def-item>
<term>iPSC</term>
<def>
<p id="Par7">Induced pluripotent stem cell</p>
</def>
</def-item>
<def-item>
<term>NRXN</term>
<def>
<p id="Par8">Neurexin</p>
</def>
</def-item>
<def-item>
<term>VGCC</term>
<def>
<p id="Par9">Voltage-gated calcium channel</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<sec>
<title>Supplementary information</title>
<p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13229-019-0303-3.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors thank Dr. Enda O’Connell for technical assistance and the Irish Government’s Programme for Research in Third Level Institutions, cycles 4 and 5, National Development Plan 2007–2013. The authors wish to thank Prof. Meng Li at Cardiff University for the training of cortical differentiation.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>SA contributed to the conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing. KM contributed to the provision of study material. JR analyzed and interpreted the data. YW collected and analyzed the data. SDB contributed to the provision of study material. VM contributed to the administrative support and provision of study material and patients. JK contributed to the administrative support and provision of study material and patients. JF contributed to the administrative support and provision of study material and patients. NF contributed to the provision of patients and collection of patient data. MOS contributed to the provision of study material and patients. AJ analyzed and interpreted the data. EBF contributed to the provision of study material and patients and collected patient data. SAL contributed to the provision of study material and patients and collected patient data. SE collected, analyzed, and interpreted the SNP data. NC contributed to the provision of study material. HP contributed to the provision of study material. PD contributed to the provision of study equipment and microscopic data analysis and interpretation. TOB contributed to the conception and design, data interpretation, manuscript writing, and final approval of the manuscript. LRQ contributed to the conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing. SS contributed to the conception and design, assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript. LG contributed to the conception and design, provision of patients, assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>Authors wish to acknowledge the Science Foundation Ireland (grant 13/IA/1787 to S.S. and L.G., 16/RC/3948 to FutureNeuro), Galway University Foundation, China Scholarship Council, and National University of Ireland Galway (grant RSU002 to S.S.) for funding the research.</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>Data are available on request from the corresponding author.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par45">Ethical approval for the study was obtained from the St. James’s/Tallaght University Hospital and the Galway University Hospital Clinical Research Ethics Committee.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par46">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Schumann</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Nordahl</surname>
<given-names>CW</given-names>
</name>
</person-group>
<article-title>Neuroanatomy of autism</article-title>
<source/>Trends Neurosci
          <year>2008</year>
<volume>31</volume>
<fpage>137</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2007.12.005</pub-id>
<pub-id pub-id-type="pmid">18258309</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubenstein</surname>
<given-names>JLR</given-names>
</name>
<name>
<surname>Merzenich</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Model of autism: increased ratio of excitation/inhibition in key neural systems</article-title>
<source/>Genes Brain Behav
          <year>2003</year>
<volume>2</volume>
<fpage>255</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="doi">10.1034/j.1601-183X.2003.00037.x</pub-id>
<pub-id pub-id-type="pmid">14606691</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Martino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fair</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Satterthwaite</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Castellanos</surname>
<given-names>FX</given-names>
</name>
<name>
<surname>Thomason</surname>
<given-names>ME</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Unraveling the miswired connectome: a developmental perspective</article-title>
<source/>Neuron
          <year>2014</year>
<volume>83</volume>
<fpage>1335</fpage>
<lpage>1353</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2014.08.050</pub-id>
<pub-id pub-id-type="pmid">25233316</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>OH</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Blue</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Pevsner</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Postmortem brain abnormalities of the glutamate neurotransmitter system in autism</article-title>
<source/>Neurology.
          <year>2001</year>
<volume>57</volume>
<fpage>1618</fpage>
<lpage>1628</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.57.9.1618</pub-id>
<pub-id pub-id-type="pmid">11706102</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatemi</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Folsom</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Kneeland</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Liesch</surname>
<given-names>SB</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism</article-title>
<source/>Anat Rec (Hoboken)
          <year>2011</year>
<volume>294</volume>
<fpage>1635</fpage>
<lpage>1645</lpage>
<pub-id pub-id-type="doi">10.1002/ar.21299</pub-id>
<pub-id pub-id-type="pmid">21901840</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariani</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Abyzov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Provini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tomasini</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders</article-title>
<source/>Cell
          <year>2015</year>
<volume>162</volume>
<fpage>375</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.06.034</pub-id>
<pub-id pub-id-type="pmid">26186191</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgeron</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A synaptic trek to autism</article-title>
<source/>Curr Opin Neurobiol
          <year>2009</year>
<volume>19</volume>
<fpage>231</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2009.06.003</pub-id>
<pub-id pub-id-type="pmid">19545994</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pagnamenta</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Klei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Anney</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional impact of global rare copy number variation in autism spectrum disorders</article-title>
<source/>Nature.
          <year>2010</year>
<volume>466</volume>
<fpage>368</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="doi">10.1038/nature09146</pub-id>
<pub-id pub-id-type="pmid">20531469</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Delaby</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Merikangas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Klei</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Convergence of genes and cellular pathways dysregulated in autism spectrum disorders</article-title>
<source/>Am J Hum Genet
          <year>2014</year>
<volume>94</volume>
<fpage>677</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2014.03.018</pub-id>
<pub-id pub-id-type="pmid">24768552</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Noor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Lionel</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Feuk</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Skaug</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural variation of chromosomes in autism spectrum disorder</article-title>
<source/>Am J Hum Genet
          <year>2008</year>
<volume>82</volume>
<fpage>477</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2007.12.009</pub-id>
<pub-id pub-id-type="pmid">18252227</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gerstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>RNA-Seq: a revolutionary tool for transcriptomics</article-title>
<source/>Nat Rev Genet
          <year>2009</year>
<volume>10</volume>
<fpage>57</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2484</pub-id>
<pub-id pub-id-type="pmid">19015660</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bucan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abrahams</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Glessner</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Sonnenblick</surname>
<given-names>LI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes</article-title>
<source/>PLoS Genet
          <year>2009</year>
<volume>5</volume>
<fpage>e1000536</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1000536</pub-id>
<pub-id pub-id-type="pmid">19557195</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ching</surname>
<given-names>MSL</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>W-H</given-names>
</name>
<name>
<surname>Jeste</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2010</year>
<volume>153B</volume>
<fpage>937</fpage>
<lpage>947</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.31063</pub-id>
<pub-id pub-id-type="pmid">20468056</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Béna</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Ravenswaaij-Arts</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stark</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dijkhuizen</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2013</year>
<volume>162B</volume>
<fpage>388</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32148</pub-id>
<pub-id pub-id-type="pmid">23533028</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viñas-Jornet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Esteba-Castillo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gabau</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ribas-Vidal</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Baena</surname>
<given-names>N</given-names>
</name>
<name>
<surname>San</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A common cognitive, psychiatric, and dysmorphic phenotype in carriers of NRXN1 deletion</article-title>
<source/>Mol Genet Genomic Med
          <year>2014</year>
<volume>2</volume>
<fpage>512</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1002/mgg3.105</pub-id>
<pub-id pub-id-type="pmid">25614873</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Need</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weale</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Maia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heinzen</surname>
<given-names>EL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A genome-wide investigation of SNPs and CNVs in schizophrenia</article-title>
<source/>PLoS Genet
          <year>2009</year>
<volume>5</volume>
<fpage>e1000373</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1000373</pub-id>
<pub-id pub-id-type="pmid">19197363</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirov</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>JTR</given-names>
</name>
<name>
<surname>Escott-Price</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Georgieva</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>AL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The penetrance of copy number variations for schizophrenia and developmental delay</article-title>
<source/>Biol Psychiatry
          <year>2014</year>
<volume>75</volume>
<fpage>378</fpage>
<lpage>385</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.07.022</pub-id>
<pub-id pub-id-type="pmid">23992924</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vrijenhoek</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Buizer-Voskamp</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>van der Stelt</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Strengman</surname>
<given-names>E</given-names>
</name>
<collab>Genetic risk and outcome in psychosis (GROUP) consortium</collab>
<name>
<surname>Sabatti</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recurrent CNVs disrupt three candidate genes in schizophrenia patients</article-title>
<source/>Am J Hum Genet
          <year>2008</year>
<volume>83</volume>
<fpage>504</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2008.09.011</pub-id>
<pub-id pub-id-type="pmid">18940311</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rujescu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ingason</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cichon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pietiläinen</surname>
<given-names>OPH</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Toulopoulou</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disruption of the neurexin 1 gene is associated with schizophrenia</article-title>
<source/>Hum Mol Genet
          <year>2009</year>
<volume>18</volume>
<fpage>988</fpage>
<lpage>996</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddn351</pub-id>
<pub-id pub-id-type="pmid">18945720</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Todarello</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kolachana</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vakkalanka</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bertolino</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Incomplete penetrance of NRXN1 deletions in families with schizophrenia</article-title>
<source/>Schizophr Res
          <year>2014</year>
<volume>155</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2014.02.023</pub-id>
<pub-id pub-id-type="pmid">24680031</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zahir</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Baross</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Eydoux</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Pugh</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1alpha</article-title>
<source/>J Med Genet
          <year>2008</year>
<volume>45</volume>
<fpage>239</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.054437</pub-id>
<pub-id pub-id-type="pmid">18057082</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiśniowiecka-Kowalnik</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nesteruk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Savage</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intragenic rearrangements in NRXN1 in three families with autism spectrum disorder, developmental delay, and speech delay</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2010</year>
<volume>153B</volume>
<fpage>983</fpage>
<lpage>993</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.31064</pub-id>
<pub-id pub-id-type="pmid">20162629</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bijlsma</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Ekici</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Engels</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1</article-title>
<source/>BMC Med Genet
          <year>2011</year>
<volume>12</volume>
<fpage>106</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2350-12-106</pub-id>
<pub-id pub-id-type="pmid">21827697</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Møller</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>YG</given-names>
</name>
<name>
<surname>Klitten</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Trucks</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Muhle</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>WS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exon-disrupting deletions of NRXN1 in idiopathic generalized epilepsy</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>256</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12078</pub-id>
<pub-id pub-id-type="pmid">23294455</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaaf</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Boone</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Sampath</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic spectrum and genotype-phenotype correlations of NRXN1 exon deletions</article-title>
<source/>Eur J Hum Genet
          <year>2012</year>
<volume>20</volume>
<fpage>1240</fpage>
<lpage>1247</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2012.95</pub-id>
<pub-id pub-id-type="pmid">22617343</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dabell</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Escobar</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>El-Khechen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vallee</surname>
<given-names>SE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Investigation of NRXN1 deletions: clinical and molecular characterization</article-title>
<source/>Am J Med Genet A
          <year>2013</year>
<volume>161A</volume>
<fpage>717</fpage>
<lpage>731</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.35780</pub-id>
<pub-id pub-id-type="pmid">23495017</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etherton</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Blaiss</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Mouse neurexin-1α deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2009</year>
<volume>106</volume>
<issue>42</issue>
<fpage>17998</fpage>
<lpage>18003</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0910297106</pub-id>
<pub-id pub-id-type="pmid">19822762</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Missler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rohlmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kattenstroth</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hammerk</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gottmann</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>a-Neurexins couple Ca21 channels to synaptic vesicle exocytosis</article-title>
<source/>Nature
          <year>2003</year>
<volume>423</volume>
<issue>6943</issue>
<fpage>939</fpage>
<lpage>948</lpage>
<pub-id pub-id-type="doi">10.1038/nature01755</pub-id>
<pub-id pub-id-type="pmid">12827191</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fucile</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Ca2+ permeability of nicotinic acetylcholine receptors</article-title>
<source/>Cell Calcium
          <year>2004</year>
<volume>35</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceca.2003.08.006</pub-id>
<pub-id pub-id-type="pmid">14670366</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catterall</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Few</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>Calcium channel regulation and presynaptic plasticity</article-title>
<source/>Neuron.
          <year>2008</year>
<volume>59</volume>
<fpage>882</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2008.09.005</pub-id>
<pub-id pub-id-type="pmid">18817729</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dudanova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sedej</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Masius</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sargsyan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Important contribution of alpha-neurexins to Ca2+-triggered exocytosis of secretory granules</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<fpage>10599</fpage>
<lpage>10613</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1913-06.2006</pub-id>
<pub-id pub-id-type="pmid">17035546</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname>
<given-names>X-J</given-names>
</name>
<name>
<surname>López-Soto</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nedelcu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lipscombe</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Retrograde synaptic inhibition is mediated by α-neurexin binding to the α2δ subunits of N-type calcium channels</article-title>
<source/>Neuron
          <year>2017</year>
<volume>95</volume>
<fpage>326</fpage>
<lpage>340.e5</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.06.018</pub-id>
<pub-id pub-id-type="pmid">28669545</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ichtchenko</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ullrich</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Missler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moomaw</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroligin 1: a splice site-specific ligand for beta-neurexins</article-title>
<source/>Cell.
          <year>1995</year>
<volume>81</volume>
<fpage>435</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(95)90396-8</pub-id>
<pub-id pub-id-type="pmid">7736595</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Ichtchenko</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Brose</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1999</year>
<volume>96</volume>
<fpage>1100</fpage>
<lpage>1105</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.96.3.1100</pub-id>
<pub-id pub-id-type="pmid">9927700</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berninghausen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>J-P</given-names>
</name>
<name>
<surname>Davletov</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ushkaryov</surname>
<given-names>YA</given-names>
</name>
</person-group>
<article-title>Neurexin Ibeta and neuroligin are localized on opposite membranes in mature central synapses</article-title>
<source/>J Neurochem
          <year>2007</year>
<volume>103</volume>
<fpage>1855</fpage>
<lpage>1863</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.04918.x</pub-id>
<pub-id pub-id-type="pmid">17868325</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Aoto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tabuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Földy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Covy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>AX</given-names>
</name>
<etal></etal>
</person-group>
<article-title>β-Neurexins control neural circuits by regulating synaptic endocannabinoid signaling</article-title>
<source/>Cell.
          <year>2015</year>
<volume>162</volume>
<fpage>593</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.06.056</pub-id>
<pub-id pub-id-type="pmid">26213384</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pak</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Danko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aoto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Maxeiner</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1</article-title>
<source/>Cell Stem Cell
          <year>2015</year>
<volume>17</volume>
<fpage>316</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2015.07.017</pub-id>
<pub-id pub-id-type="pmid">26279266</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belmonte</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Gomot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Visual attention in autism families: “unaffected” sibs share atypical frontal activation</article-title>
<source/>J Child Psychol Psychiatry
          <year>2010</year>
<volume>51</volume>
<fpage>259</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-7610.2009.02153.x</pub-id>
<pub-id pub-id-type="pmid">19912448</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dichter</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Felder</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Bodfish</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Autism is characterized by dorsal anterior cingulate hyperactivation during social target detection</article-title>
<source/>Soc Cogn Affect Neurosci
          <year>2009</year>
<volume>4</volume>
<fpage>215</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1093/scan/nsp017</pub-id>
<pub-id pub-id-type="pmid">19574440</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orekhova</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Stroganova</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Nygren</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tsetlin</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Posikera</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excess of high frequency electroencephalogram oscillations in boys with autism</article-title>
<source/>Biol Psychiatry
          <year>2007</year>
<volume>62</volume>
<fpage>1022</fpage>
<lpage>1029</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2006.12.029</pub-id>
<pub-id pub-id-type="pmid">17543897</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Billstedt</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Autism and Asperger syndrome: coexistence with other clinical disorders</article-title>
<source/>Acta Psychiatr Scand
          <year>2000</year>
<volume>102</volume>
<fpage>321</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1034/j.1600-0447.2000.102005321.x</pub-id>
<pub-id pub-id-type="pmid">11098802</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canitano</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Epilepsy in autism spectrum disorders</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2007</year>
<volume>16</volume>
<fpage>61</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-006-0563-2</pub-id>
<pub-id pub-id-type="pmid">16932856</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<mixed-citation publication-type="other">Deneault E, Faheem M, White SH, Rodrigues DC, Sun S, Wei W, et al. CNTN5-/+or EHMT2-/+human iPSC-derived neurons from individuals with autism develop hyperactive neuronal networks. Elife. 2019;8. 10.7554/eLife.40092.</mixed-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</article-title>
<source/>Cell.
          <year>2006</year>
<volume>126</volume>
<fpage>663</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.07.024</pub-id>
<pub-id pub-id-type="pmid">16904174</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohnuki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Narita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ichisaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tomoda</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>
<source/>Cell
          <year>2007</year>
<volume>131</volume>
<fpage>861</fpage>
<lpage>872</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id>
<pub-id pub-id-type="pmid">18035408</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Strategies and new developments in the generation of patient-specific pluripotent stem cells</article-title>
<source/>Cell Stem Cell
          <year>2007</year>
<volume>1</volume>
<fpage>39</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2007.05.012</pub-id>
<pub-id pub-id-type="pmid">18371333</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Courchesne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Redcay</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>The autistic brain: birth through adulthood</article-title>
<source/>Curr Opin Neurol
          <year>2004</year>
<volume>17</volume>
<fpage>489</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1097/01.wco.0000137542.14610.b4</pub-id>
<pub-id pub-id-type="pmid">15247547</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casanova</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>El-Baz</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Kamat</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Dombroski</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Khalifa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Elnakib</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Focal cortical dysplasias in autism spectrum disorders</article-title>
<source/>Acta Neuropathol Commun
          <year>2013</year>
<volume>1</volume>
<fpage>67</fpage>
<pub-id pub-id-type="doi">10.1186/2051-5960-1-67</pub-id>
<pub-id pub-id-type="pmid">24252498</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ecker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ginestet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>M-C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain surface anatomy in adults with autism: the relationship between surface area, cortical thickness, and autistic symptoms</article-title>
<source/>JAMA Psychiatry
          <year>2013</year>
<volume>70</volume>
<fpage>59</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.265</pub-id>
<pub-id pub-id-type="pmid">23404046</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la Torre-Ubieta</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Advancing the understanding of autism disease mechanisms through genetics</article-title>
<source/>Nat Med
          <year>2016</year>
<volume>22</volume>
<fpage>345</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="doi">10.1038/nm.4071</pub-id>
<pub-id pub-id-type="pmid">27050589</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varghese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Keshav</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jacot-Descombes</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Warda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wicinski</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dickstein</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism spectrum disorder: neuropathology and animal models</article-title>
<source/>Acta Neuropathol
          <year>2017</year>
<volume>134</volume>
<fpage>537</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-017-1736-4</pub-id>
<pub-id pub-id-type="pmid">28584888</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chambers</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Fasano</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Papapetrou</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Tomishima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sadelain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Studer</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling</article-title>
<source/>Nat Biotechnol
          <year>2009</year>
<volume>27</volume>
<fpage>275</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.1529</pub-id>
<pub-id pub-id-type="pmid">19252484</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kirwan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Livesey</surname>
<given-names>FJ</given-names>
</name>
</person-group>
<article-title>Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks</article-title>
<source/>Nat Protoc
          <year>2012</year>
<volume>7</volume>
<fpage>1836</fpage>
<lpage>1846</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2012.116</pub-id>
<pub-id pub-id-type="pmid">22976355</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Flinter</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Domínguez</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ulk4 regulates neural stem cell pool</article-title>
<source/>Stem Cells
          <year>2016</year>
<volume>34</volume>
<fpage>2318</fpage>
<lpage>2331</lpage>
<pub-id pub-id-type="doi">10.1002/stem.2423</pub-id>
<pub-id pub-id-type="pmid">27300315</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lalor</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>U</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ulk4 is essential for ciliogenesis and CSF flow</article-title>
<source/>J Neurosci
          <year>2016</year>
<volume>36</volume>
<fpage>7589</fpage>
<lpage>7600</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0621-16.2016</pub-id>
<pub-id pub-id-type="pmid">27445138</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fitzgibbon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Reilly</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>X</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ulk4 regulates GABAergic signaling and anxiety-related behavior</article-title>
<source/>Transl Psychiatry
          <year>2018</year>
<volume>8</volume>
<fpage>43</fpage>
<pub-id pub-id-type="doi">10.1038/s41398-017-0091-5</pub-id>
<pub-id pub-id-type="pmid">29391390</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Dockery</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>U</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ulk4 deficiency leads to hypomyelination in mice</article-title>
<source/>Glia.
          <year>2018</year>
<volume>66</volume>
<fpage>175</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1002/glia.23236</pub-id>
<pub-id pub-id-type="pmid">29034508</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohart</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gautier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lê Cao</surname>
<given-names>K-A</given-names>
</name>
</person-group>
<article-title>mixOmics: an R package for ‘omics feature selection and multiple data integration</article-title>
<source/>PLoS Comput Biol
          <year>2017</year>
<volume>13</volume>
<fpage>e1005752</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1005752</pub-id>
<pub-id pub-id-type="pmid">29099853</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Neuroligins and neurexins link synaptic function to cognitive disease</article-title>
<source/>Nature.
          <year>2008</year>
<volume>455</volume>
<fpage>903</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1038/nature07456</pub-id>
<pub-id pub-id-type="pmid">18923512</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology</article-title>
<source/>Stem Cells
          <year>2010</year>
<volume>28</volume>
<fpage>885</fpage>
<lpage>893</lpage>
<pub-id pub-id-type="doi">10.1002/stem.419</pub-id>
<pub-id pub-id-type="pmid">20333750</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Splawski</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Timothy</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Sharpe</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Decher</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>CaV1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism</article-title>
<source/>Cell
          <year>2004</year>
<volume>119</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2004.09.011</pub-id>
<pub-id pub-id-type="pmid">15454078</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Splawski</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Timothy</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Decher</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sachse</surname>
<given-names>FB</given-names>
</name>
<name>
<surname>Beggs</surname>
<given-names>AH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2005</year>
<volume>102</volume>
<fpage>8089</fpage>
<lpage>8096</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0502506102</pub-id>
<pub-id pub-id-type="pmid">15863612</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ronemus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hakker</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rosenbaum</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo gene disruptions in children on the autistic spectrum</article-title>
<source/>Neuron.
          <year>2012</year>
<volume>74</volume>
<fpage>285</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.04.009</pub-id>
<pub-id pub-id-type="pmid">22542183</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Karakoc</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Krumm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<fpage>246</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1038/nature10989</pub-id>
<pub-id pub-id-type="pmid">22495309</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Rubeis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Poultney</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Samocha</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cicek</surname>
<given-names>AE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>
<source/>Nature.
          <year>2014</year>
<volume>515</volume>
<fpage>209</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1038/nature13772</pub-id>
<pub-id pub-id-type="pmid">25363760</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinggera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lieb</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lampert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Monteleone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liedl</surname>
<given-names>KR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3 L-type calcium channels</article-title>
<source/>Biol Psychiatry
          <year>2015</year>
<volume>77</volume>
<fpage>816</fpage>
<lpage>822</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2014.11.020</pub-id>
<pub-id pub-id-type="pmid">25620733</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinggera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mackenroth</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rump</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schallner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beleggia</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wollnik</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy</article-title>
<source/>Hum Mol Genet
          <year>2017</year>
<volume>26</volume>
<fpage>2923</fpage>
<lpage>2932</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddx175</pub-id>
<pub-id pub-id-type="pmid">28472301</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruderfer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Solovieff</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Roussos</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A polygenic burden of rare disruptive mutations in schizophrenia</article-title>
<source/>Nature.
          <year>2014</year>
<volume>506</volume>
<fpage>185</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1038/nature12975</pub-id>
<pub-id pub-id-type="pmid">24463508</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sundararajan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Manzardo</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases</article-title>
<source/>Gene.
          <year>2018</year>
<volume>641</volume>
<fpage>25</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2017.10.035</pub-id>
<pub-id pub-id-type="pmid">29032150</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Cross-Disorder Group of the Psychiatric Genomics Consortium</collab>
</person-group>
<article-title>Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis</article-title>
<source/>Lancet
          <year>2013</year>
<volume>381</volume>
<fpage>1371</fpage>
<lpage>1379</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(12)62129-1</pub-id>
<pub-id pub-id-type="pmid">23453885</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borlot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Stavropoulos</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Prevalence of pathogenic copy number variation in adults with pediatric-onset epilepsy and intellectual disability</article-title>
<source/>JAMA Neurol
          <year>2017</year>
<volume>74</volume>
<fpage>1301</fpage>
<lpage>1311</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2017.1775</pub-id>
<pub-id pub-id-type="pmid">28846756</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breitenkamp</surname>
<given-names>AFS</given-names>
</name>
<name>
<surname>Matthes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nass</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Sinzig</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lehmkuhl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nürnberg</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare mutations of CACNB2 found in autism spectrum disease-affected families alter calcium channel function</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e95579</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0095579</pub-id>
<pub-id pub-id-type="pmid">24752249</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soldatov</surname>
<given-names>NM</given-names>
</name>
</person-group>
<article-title>CACNB2: an emerging pharmacological target for hypertension, heart failure, arrhythmia and mental disorders</article-title>
<source/>Curr Mol Pharmacol
          <year>2015</year>
<volume>8</volume>
<fpage>32</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.2174/1874467208666150507093258</pub-id>
<pub-id pub-id-type="pmid">25966706</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gershon</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Grennan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Busnello</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Badner</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ovsiew</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Memon</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A rare mutation of CACNA1C in a patient with bipolar disorder, and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain</article-title>
<source/>Mol Psychiatry
          <year>2014</year>
<volume>19</volume>
<fpage>890</fpage>
<lpage>894</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2013.107</pub-id>
<pub-id pub-id-type="pmid">23979604</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamdan</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Gauthier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>D-T</given-names>
</name>
<name>
<surname>Yoshizawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Higashi</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability</article-title>
<source/>Am J Hum Genet
          <year>2011</year>
<volume>88</volume>
<fpage>306</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2011.02.001</pub-id>
<pub-id pub-id-type="pmid">21376300</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Földy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ilcus</surname>
<given-names>SMC</given-names>
</name>
<name>
<surname>Tabuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Distinct circuit-dependent functions of presynaptic neurexin-3 at GABAergic and glutamatergic synapses</article-title>
<source/>Nat Neurosci
          <year>2015</year>
<volume>18</volume>
<fpage>997</fpage>
<lpage>1007</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4037</pub-id>
<pub-id pub-id-type="pmid">26030848</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gokce</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Conditional deletion of all neurexins defines diversity of essential synaptic organizer functions for neurexins</article-title>
<source/>Neuron
          <year>2017</year>
<volume>94</volume>
<fpage>611</fpage>
<lpage>625.e4</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.04.011</pub-id>
<pub-id pub-id-type="pmid">28472659</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Synaptic neurexin complexes: a molecular code for the logic of neural circuits</article-title>
<source/>Cell.
          <year>2017</year>
<volume>171</volume>
<fpage>745</fpage>
<lpage>769</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.10.024</pub-id>
<pub-id pub-id-type="pmid">29100073</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nanou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Catterall</surname>
<given-names>WA</given-names>
</name>
</person-group>
<article-title>Calcium channels, synaptic plasticity, and neuropsychiatric disease</article-title>
<source/>Neuron
          <year>2018</year>
<volume>98</volume>
<fpage>466</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2018.03.017</pub-id>
<pub-id pub-id-type="pmid">29723500</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brockhaus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schreitmüller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Repetto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Klatt</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Reissner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Elmslie</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>α-Neurexins together with α2δ-1 auxiliary subunits regulate Ca2+ influx through Cav2.1 channels</article-title>
<source/>J Neurosci
          <year>2018</year>
<volume>38</volume>
<fpage>8277</fpage>
<lpage>8294</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0511-18.2018</pub-id>
<pub-id pub-id-type="pmid">30104341</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsigelny</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Shindyalov</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Bourne</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Common EF-hand motifs in cholinesterases and neuroligins suggest a role for Ca2+ binding in cell surface associations</article-title>
<source/>Protein Sci
          <year>2000</year>
<volume>9</volume>
<fpage>180</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="doi">10.1110/ps.9.1.180</pub-id>
<pub-id pub-id-type="pmid">10739260</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Davletov</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Petrenko</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Jahn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Interaction of synaptotagmin with the cytoplasmic domains of neurexins</article-title>
<source/>Neuron.
          <year>1993</year>
<volume>10</volume>
<fpage>307</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1016/0896-6273(93)90320-Q</pub-id>
<pub-id pub-id-type="pmid">8439414</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Neurexin-NSF interaction regulates short-term synaptic depression</article-title>
<source/>J Biol Chem
          <year>2015</year>
<volume>290</volume>
<fpage>17656</fpage>
<lpage>17667</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M115.644583</pub-id>
<pub-id pub-id-type="pmid">25953899</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krey</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Dolmetsch</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of autism: a possible role for Ca2+ signaling</article-title>
<source/>Curr Opin Neurobiol
          <year>2007</year>
<volume>17</volume>
<issue>1</issue>
<fpage>112</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2007.01.010</pub-id>
<pub-id pub-id-type="pmid">17275285</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breitenkamp</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Matthes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herzig</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Voltage-gated calcium channels and autism spectrum disorders</article-title>
<source/>Curr Mol Pharmacol
          <year>2015</year>
<volume>8</volume>
<issue>2</issue>
<fpage>123</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="doi">10.2174/1874467208666150507105235</pub-id>
<pub-id pub-id-type="pmid">25966693</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heyes</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pratt</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dahimene</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ferron</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders</article-title>
<source/>Prog Neurobiol
          <year>2015</year>
<volume>134</volume>
<fpage>36</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2015.09.002</pub-id>
<pub-id pub-id-type="pmid">26386135</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zamponi</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>Targeting voltage-gated calcium channels in neurological and psychiatric diseases</article-title>
<source/>Nat Rev Drug Discov
          <year>2016</year>
<volume>15</volume>
<fpage>19</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1038/nrd.2015.5</pub-id>
<pub-id pub-id-type="pmid">26542451</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connell</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>McGregor</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Lochner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Emsley</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Warnich</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>The genetic architecture of schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder</article-title>
<source/>Mol Cell Neurosci
          <year>2018</year>
<volume>88</volume>
<fpage>300</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2018.02.010</pub-id>
<pub-id pub-id-type="pmid">29505902</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tadross</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Tsien</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Sequential ionic and conformational signaling by calcium channels drives neuronal gene expression</article-title>
<source/>Science.
          <year>2016</year>
<volume>351</volume>
<fpage>863</fpage>
<lpage>867</lpage>
<pub-id pub-id-type="doi">10.1126/science.aad3647</pub-id>
<pub-id pub-id-type="pmid">26912895</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McFadden</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB</article-title>
<source/>Neuron.
          <year>1990</year>
<volume>4</volume>
<fpage>571</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="doi">10.1016/0896-6273(90)90115-V</pub-id>
<pub-id pub-id-type="pmid">2157471</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zafra</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hengerer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Leibrock</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thoenen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lindholm</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors</article-title>
<source/>EMBO J
          <year>1990</year>
<volume>9</volume>
<fpage>3545</fpage>
<lpage>3550</lpage>
<pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb07564.x</pub-id>
<pub-id pub-id-type="pmid">2170117</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graef</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Mermelstein</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Stankunas</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Neilson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Deisseroth</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tsien</surname>
<given-names>RW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons</article-title>
<source/>Nature.
          <year>1999</year>
<volume>401</volume>
<fpage>703</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="doi">10.1038/44378</pub-id>
<pub-id pub-id-type="pmid">10537109</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardingham</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Chawla</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cruzalegui</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Bading</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels</article-title>
<source/>Neuron
          <year>1999</year>
<volume>22</volume>
<fpage>789</fpage>
<lpage>798</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(00)80737-0</pub-id>
<pub-id pub-id-type="pmid">10230798</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Bonni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nadal-Vicens</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Neuronal activity-dependent cell survival mediated by transcription factor MEF2</article-title>
<source/>Science
          <year>1999</year>
<volume>286</volume>
<fpage>785</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="doi">10.1126/science.286.5440.785</pub-id>
<pub-id pub-id-type="pmid">10531066</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>